Biosense Webster, Inc.

This study tests a new catheter called VARIPULSE against an already-approved one (FARAWAVE) for people with persistent atrial fibrillation, a condition where the heart beats irregularly for over a week. About 466 participants will receive one of the two treatments to see which is…

This study is testing a new system (VARIPULSE catheter and TRUPULSE generator) with updated software to treat atrial fibrillation, a condition where the heart beats irregularly. About 50 adults with either short-lasting (paroxysmal) or longer-lasting (persistent) atrial fibrillat…

This study tests a new device that uses quick electric pulses to fix faulty heart signals in people with a type of irregular heartbeat called paroxysmal atrial fibrillation. About 440 adults who have not gotten relief from medication will receive the procedure. The goal is to see…

This study looks at the long-term safety and effectiveness of the VARIPULSE catheter, a device already approved by the FDA, for treating people with a type of irregular heartbeat called paroxysmal atrial fibrillation. About 276 participants will undergo a procedure to isolate the…

This study will follow 8,000 people with heart rhythm disorders who are scheduled for a standard catheter ablation procedure using approved Biosense Webster devices. The goal is to collect real-world data on how safe and effective these devices are during routine use. Participant…

This study is testing a new, paddle-shaped catheter designed to map abnormal heart rhythms (arrhythmias) in people with conditions like atrial fibrillation or ventricular tachycardia. About 60 participants will undergo a standard heart-mapping procedure using this investigational…